ISX and hepatocellular carcinoma: To explore whether or not ISX, BRD4, and PCAF are also co‐expressed in HCC and modulate the outcome of tumor severity, in this study, we collected the hepatitis specimens from 377 patients with HCC to explore how PCAF, BRD4, and ISX, respectively, and collaboratively impact on liver cancer tumors and the correlation with the prognosis of patients with HCC are discussed.